Floatz logo

Neoantigen Dna Vaccine

Metastatic Hormone-Sensitive Prostate Cancer

Washington University School of MedicinevaccinePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

514 Active assets in the Metastatic Hormone-Sensitive Prostate Cancer cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB

View all 50 →

Same molecule, other indications

Neoantigen Dna Vaccine is also rated in:

small cell lung carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →